| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. | President and CEO, Director | Common Stock | 607K | $3.25M | $5.35 | Jan 2, 2024 | Direct |
| Atara Biotherapeutics, Inc. | Chief Commercial Officer | Common Stock | 171K | $66.7K | $0.39 | Mar 1, 2022 | Direct |
| Poseida Therapeutics, Inc. | President and CEO, Director | Stock Option (Right to buy) | 345K | Jan 2, 2024 | Direct | ||
| Atara Biotherapeutics, Inc. | Chief Commercial Officer | Employee Stock Option (Right to Buy) | 85.6K | Mar 1, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PSTX | Poseida Therapeutics, Inc. | Jan 2, 2024 | 2 | $0 | 4 | Jan 4, 2024 | President and CEO, Director |
| PSTX | Poseida Therapeutics, Inc. | Apr 11, 2023 | 2 | $0 | 4 | Apr 12, 2023 | President, Cell Therapy |
| PSTX | Poseida Therapeutics, Inc. | Apr 11, 2023 | 0 | $0 | 3 | Apr 12, 2023 | President, Cell Therapy |
| ATRA | Atara Biotherapeutics, Inc. | Mar 1, 2022 | 2 | $0 | 4 | Mar 3, 2022 | Chief Commercial Officer |
| ATRA | Atara Biotherapeutics, Inc. | Jun 11, 2021 | 3 | $500K | 4 | Jun 15, 2021 | Chief Commercial Officer |
| ATRA | Atara Biotherapeutics, Inc. | May 18, 2021 | 1 | -$11.1K | 4 | May 20, 2021 | Chief Commercial Officer |